The trial is a multicenter.

‘If the disease progresses, behavioral problems often and in frequency severity increase. No approved therapies for agitation with dementia, managing the symptoms can be challenging together. This study is an important first step in potential. Therapy for managing symptoms of agitation in Alzheimer ‘s disease ‘.. AVPnir Pharmaceuticals Enrolls First Patient in Study AVP-923 for the treatment of agitation in Alzheimer’s patients[ Professional Services Close – Up]The objectives of this proof-of-concept study is to evaluate safety, tolerability and efficacy of AVP – 923 evaluated for the treatment of agitation in Alzheimer’s patients.

Avanir Pharmaceuticals is a biopharmaceutical company focused on the development of drugs for patients with disorders of the central nervous system.Germany pharmaceuticals R & E be second only to the U.S. In discovering of the most successful drug. One quarter of the top global 100th medication come from Britain. Based Pharmaceutical Industry in Germany reinvests more than 34 % of its sales in research into new medications.

Boom In Medicines Research in the United Kingdom Under Threatsignal warning sign that the boom in medical research are threatened in Britain are already been today from the Association British Pharmaceutical Industry .